PARP1 and ovarian carcinoma: Notably, the PARP1 inhibitor talazoparib (BMN 673) elicited increased numbers of peritoneal CD8+ T cells and NK cells in an ovarian cancer mouse model and increased infiltration into ex vivo spheroids, in addition to increasing IFNγ and TNFα production levels62,63.